The small GTPase Ras-related C3 botulinum toxin substrate 1B (RAC1B) has been shown to potently inhibit transforming growth factor (TGF)-β1-induced cell migration and epithelial-mesenchymal transition (EMT) in pancreatic and breast epithelial cells, but the underlying mechanism has remained obscure. Using a panel of pancreatic ductal adenocarcinoma (PDAC)-derived cell lines of different differentiation stages, we show that RAC1B is more abundantly expressed in well differentiated as opposed to poorly differentiated cells. Interestingly, RNA interference-mediated knockdown of RAC1B decreased expression of the epithelial marker protein E-cadherin, encoded by CDH1, and enhanced its TGF-β1-induced downregulation, whereas ectopic overexpression of RAC1B upregulated CDH1 expression and largely prevented its TGF-β1-induced silencing of CDH1. Conversely, knockdown of RAC1B, or deletion of the RAC1B-specific exon 3b by CRISPR/Cas-mediated genomic editing, enhanced basal and TGF-β1-induced upregulation of mesenchymal markers like Vimentin, and EMT-associated transcription factors such as SNAIL and SLUG. Moreover, we demonstrate that knockout of RAC1B enhanced the cells' migratory activity and derepressed TGF-β1-induced activation of the mitogen-activated protein kinase ERK2. Pharmacological inhibition of ERK1/2 activation in RAC1B-depleted cells rescued cells from the RAC1B knockdown-induced enhancement of cell migration, TGF-β1-induced downregulation of CDH1, and upregulation of SNAI1. We conclude that RAC1B promotes epithelial gene expression and suppresses mesenchymal gene expression by interfering with TGF-β1-induced MEK-ERK signaling, thereby protecting cells from undergoing EMT and EMT-associated responses like acquisition of cell motility.
Introduction
The human RAC1 gene, by alternative splicing, gives rise to two proteins designated Ras-related C3 botulinum toxin substrate 1 (RAC1) and RAC1B. Both proteins belong to the Rho family of monomeric GTPases with RAC1B differing from RAC1 by the presence of an additional exon (exon 3b) of 19 amino acids in length. Biochemically, the in-frame insertion of exon 3b results in an accelerated GDP/GTP-exchange and an impaired GTP-hydrolysis compared to RAC1. In addition, RAC1B differs from RAC1 by the type of upstream activators, binding partners, and downstream effectors/targets, although only few RAC1B-specific target genes have been identified so far. RAC1B has been implicated in tumor progression by its ability to promote cell cycle progression and apoptosis resistance in some cell types, however, its role in other processes driving malignant transformation
Results

RAC1B Expression in PDAC-Derived Cell Lines is Associated with a Well Differentiated Epithelial Phenotype
In the course of a previous study we observed that RAC1B protein was more abundant in the well differentiated PDAC-derived cell line, Colo357, than in the poorly differentiated PDAC cell line, Panc1 [18] . This finding led us to assume that RAC1B might be preferentially associated with the epithelial phenotype. To confirm this assumption, we analyzed RAC1B expression in a larger panel of well characterized permanent PDAC cell lines. Among these lines, Capan1, Capan2, and Colo357 cells have been classified as well differentiated (G1), BxPC3 as moderately differentiated (G2), and Panc1 and MiaPaCa2 as poorly differentiated (G3) based on ultrastructural features and population doubling times which were related to the grade of differentiation [27] . Intriguingly, RAC1B was expressed at higher levels in G1 and G2 cell lines compared to G3 cell lines ( Figure 1A ). Its expression pattern essentially mirrored that of E-cadherin (encoded by CDH1) and the tight junction protein Claudin-7 (encoded by CLDN7) which both were abundantly expressed in Capan2, BxPC3, and Colo357 cells but only weakly in Panc1 and MiaPaCa2 cells ( Figure 1A ). High RAC1B and E-cadherin protein expression was also observed in another well differentiated PDAC-derived cell line, Capan1, and in the benign human pancreatic ductal epithelial cell line, H6c7 [28] (Supplementary Figure S1) .
To validate the epithelial phenotype of Capan2, Colo357, and BxPC3 cells and to reveal if E-cadherin and Claudin-7 protein expression corresponds to similar changes in mRNA expression, we processed all five PDAC cell lines for qPCR-based expression analysis of RAC1B, RAC1 as control, CDH1, CLDN7, and two additional epithelial markers, Epithelial cell adhesion molecule (EpCAM, encoded by EPCAM) and Cytokeratin-19 (encoded by KRT19). Interestingly, the mRNA levels of RAC1B, CDH1, CLDN7, EPCAM, and KRT19 were all higher in the well differentiated cell lines compared to the poorly differentiated ones ( Figure 1B) . In contrast to RAC1B, mRNA levels of RAC1 differed only marginally among the cell lines ( Figure 1B) .
TGF-β1 is a powerful inhibitor of epithelial gene expression. To analyze if PDAC cells are capable of autocrine TGF-β production and if this ability correlates to cellular differentiation stages we measured the concentration of biologically active TGF-β1 in the culture supernatants of well differentiated Colo357 and poorly differentiated Panc1 cells. Notably, the concentration of TGF-β1 was 8-fold higher in supernatants of Panc1 than in those of Colo357 cells (Supplementary Figure S2) . Taken together, we found that RAC1B but not RAC1 expression in PDAC-derived cells is strongly correlated with a well differentiated, epithelial-like phenotype. 
RAC1B Knockdown is Associated with a Decrease in CDH1 Expression, an Enhancement of TGF-β1-Induced CDH1 Downregulation, and an Increase in Cell Migration
Prompted by the association of RAC1B expression with higher epithelial differentiation in PDAC-derived cells, we addressed the question if RAC1B is causally involved in maintaining an epithelial phenotype. To do this, we inhibited RAC1B expression in Capan1, Colo357, and Panc1 cells by siRNA-mediated knockdown, targeting exon 3b of RAC1 [17, 18, 20, 21] followed by measurement of epithelial gene expression. The RAC1B knockdown resulted in downregulation of CDH1 mRNA in all three cell lines (Figure 2A) , and of CLDN7 and EPCAM mRNA in Panc1 cells (Supplementary Figure S3 , for E-cadherin protein expression in Capan1 cells see Supplementary Figure S1 ).
The silencing of genes that determine the epithelial phenotype is a crucial event in TGF-β-induced EMT. We therefore asked if RAC1B also impacts downregulation of CDH1 by TGF-β1. Interestingly, treatment of Panc1 cells with TGF-β1 further enhanced the RAC1B knockdowninduced decrease in E-cadherin protein expression ( Figure 2B ).
CDH1 is known to be a potent invasion suppressor gene [24] . Having shown that RAC1B knockdown resulted in silencing of CDH1, we reasoned that the reduction in E-cadherin protein should increase the cells' motility. To verify this assumption, we monitored spontaneous (random) migration in real-time in both control and RAC1B-depleted Colo357 and Panc1 cells. Control Colo357 cells failed to display any migratory activity during the 12-h observation period whereas Panc1 cells showed significant migratory activity ( Figure 2C ). However, the knockdown of RAC1B rendered Colo357 motile and further enhanced migration of Panc1 cells ( Figure 2C ). Together, the data so far suggest that RAC1B promotes the expression of epithelial genes and helps to prevent their Prompted by the association of RAC1B expression with higher epithelial differentiation in PDAC-derived cells, we addressed the question if RAC1B is causally involved in maintaining an epithelial phenotype. To do this, we inhibited RAC1B expression in Capan1, Colo357, and Panc1 cells by siRNA-mediated knockdown, targeting exon 3b of RAC1 [17, 18, 20, 21] followed by measurement of epithelial gene expression. The RAC1B knockdown resulted in downregulation of CDH1 mRNA in all three cell lines (Figure 2A) , and of CLDN7 and EPCAM mRNA in Panc1 cells (Supplementary Figure  S3 , for E-cadherin protein expression in Capan1 cells see Supplementary Figure S1 ).
The silencing of genes that determine the epithelial phenotype is a crucial event in TGF-β-induced EMT. We therefore asked if RAC1B also impacts downregulation of CDH1 by TGF-β1. Interestingly, treatment of Panc1 cells with TGF-β1 further enhanced the RAC1B knockdown-induced decrease in E-cadherin protein expression ( Figure 2B ).
CDH1 is known to be a potent invasion suppressor gene [24] . Having shown that RAC1B knockdown resulted in silencing of CDH1, we reasoned that the reduction in E-cadherin protein should increase the cells' motility. To verify this assumption, we monitored spontaneous (random) migration in real-time in both control and RAC1B-depleted Colo357 and Panc1 cells. Control Colo357 cells failed to display any migratory activity during the 12-h observation period whereas Panc1 cells showed significant migratory activity ( Figure 2C ). However, the knockdown of RAC1B rendered Colo357 motile and further enhanced migration of Panc1 cells ( Figure 2C ). Together, the data so far suggest 
Ectopic RAC1B Overexpression is Associated with an Increase in the Expression of Epithelial Genes and Protection from Downregulation by TGF-β
In order to confirm the regulatory interactions between RAC1B and its epithelial target genes, we employed Panc1 cells with transient ( Figure 3A Figure S4 ) [18] . In these cells, the mRNA levels of CDH1 were increased over those in empty vector control cells ( Figure  3A) . Analysis of E-cadherin expression in Panc1-HA-RAC1B cells by Western blot analysis showed 
In order to confirm the regulatory interactions between RAC1B and its epithelial target genes, we employed Panc1 cells with transient ( Figure 3A Figure S4 ) [18] . In these cells, the mRNA levels of CDH1 were increased over those in empty vector control cells ( Figure 3A ). Analysis of E-cadherin expression in Panc1-HA-RAC1B cells by Western blot analysis showed that protein levels were elevated in three of four clones compared to vector controls ( Figure 3B ). Interestingly, ectopic expression of a constitutively active RAC1 mutant (Q61L) in Panc1 cells had the opposite effect ( Figure 3B ). Likewise, 3/3 Panc1-HA-RAC1B clones exhibited more abundant mRNA expression of CLDN7 ( Figure 3C ). We then asked if RAC1B when overexpressed can protect cells from losing epithelial gene expression in response to TGF-β1 signaling. Strikingly, the ectopically expressed RAC1B partially protected Panc1 cells from the dramatic downregulation of CDH1 seen in TGF-β1-treated vector control cells ( Figure 3D ). The data show that ectopic RAC1B in contrast to ectopic RAC1 can promote epithelial gene expression and protect CDH1 from being silenced by TGF-β1. This dual function of RAC1B might enable the cell to maintain an (undifferentiated) epithelial phenotype. that protein levels were elevated in three of four clones compared to vector controls ( Figure 3B ). Interestingly, ectopic expression of a constitutively active RAC1 mutant (Q61L) in Panc1 cells had the opposite effect ( Figure 3B ). Likewise, 3/3 Panc1-HA-RAC1B clones exhibited more abundant mRNA expression of CLDN7 ( Figure 3C ). We then asked if RAC1B when overexpressed can protect cells from losing epithelial gene expression in response to TGF-β1 signaling. Strikingly, the ectopically expressed RAC1B partially protected Panc1 cells from the dramatic downregulation of CDH1 seen in TGF-β1-treated vector control cells ( Figure 3D ). The data show that ectopic RAC1B in contrast to ectopic RAC1 can promote epithelial gene expression and protect CDH1 from being silenced by TGF-β1. This dual function of RAC1B might enable the cell to maintain an (undifferentiated) epithelial phenotype. 
RAC1B Inhibits the Expression of Mesenchymal Genes and Their Upregulation by TGF-β
The observation that RAC1B expression was more abundant in well differentiated pancreatic cancer cell lines prompted us to hypothesize that RAC1B promotes epithelial differentiation not only by the upregulation of epithelial marker genes but also by blocking the route to mesenchymal differentiation. Support for this comes from previous studies showing that RAC1B suppressed SERPINE1 (encoding plasminogen-activator inhibitor 1), MMP9 (encoding MMP9) [17] , and TGFBRI (encoding the TGF-β type I receptor activin receptor-like kinase 5) [20] . Here we analyzed if the intermediate filament protein Vimentin (encoded by VIM), a marker for EMT [29] associated with pancreatic tumor budding [7] , is also targeted for inhibition by RAC1B. Strikingly, knockdown of RAC1B increased TGF-β1-regulated protein ( Figure 4A ) and mRNA (Supplementary Figure S5) expression of Vimentin indicating relief from inhibition by RAC1B. 
The observation that RAC1B expression was more abundant in well differentiated pancreatic cancer cell lines prompted us to hypothesize that RAC1B promotes epithelial differentiation not only by the upregulation of epithelial marker genes but also by blocking the route to mesenchymal differentiation. Support for this comes from previous studies showing that RAC1B suppressed SERPINE1 (encoding plasminogen-activator inhibitor 1), MMP9 (encoding MMP9) [17] , and TGFBRI (encoding the TGF-β type I receptor activin receptor-like kinase 5) [20] . Here we analyzed if the intermediate filament protein Vimentin (encoded by VIM), a marker for EMT [29] associated with pancreatic tumor budding [7] , is also targeted for inhibition by RAC1B. Strikingly, knockdown of RAC1B increased TGF-β1-regulated protein ( Figure 4A ) and mRNA (Supplementary Figure S5) 
-HA-RAC1B clones and vector control cells by qPCR revealed that HA-RAC1B strongly decreased the TGF-β1 effect ( Figure 4F ). Together, these data show that RAC1B prevents the constitutive and TGF-β-driven expression of mesenchymal genes from different classes including that of master regulators of EMT. Prompted by the finding that RAC1B downregulated a wide array of mesenchymal genes, we addressed the question of whether RAC1B might be able (i) to target master regulators of mesenchymal differentiation programs such as the EMT-associated transcription factors SNAIL (encoded by SNAI1) and SLUG (encoded by SNAI2), and (ii) to block their induction by agents that promote mesenchymal (trans)differentiation such as TGF-β. Intriguingly, RAC1B prevented upregulation by TGF-β1 of SNAI1 at both the protein ( Figure 4B ) and RNA ( Figure 4C ) level. We also noted a greatly enhanced derepression of basal and TGF-β1-induced SLUG protein in Panc1 cells with a CRISPR-Cas9 engineered genomic deletion of exon 3b of RAC1 (Panc1-RAC1B knockout cells, Figure 4D) . When compared at the mRNA level, SNAI2 induction by TGF-β1 was much stronger in the RAC1B knockout vs. knockdown cells ( Figure 4E ). Finally, we sought to know if ectopically expressed HA-RAC1B affects TGF-β1-induced upregulation of SNAI2. The quantification of SNAI2 mRNA in Panc1-HA-RAC1B clones and vector control cells by qPCR revealed that HA-RAC1B strongly decreased the TGF-β1 effect ( Figure 4F) . Together, these data show that RAC1B prevents the constitutive and TGF-β-driven expression of mesenchymal genes from different classes including that of master regulators of EMT.
Inhibition of MEK-ERK Signaling by RAC1B Underlies Its Stimulatory Effect on CDH1 and Its Repressive Effect on SNAI1 and Cell Migration
The MEK-ERK pathway is a central driver of (TGF-β-induced) EMT in cancer [30, 31] and required for cell migration and invasion in PDAC-derived cells [32] . To analyze the role of ERK activation in RAC1B-mediated control of epithelial and mesenchymal gene expression, we treated Panc1-RAC1B knockdown cells in the absence or presence of TGF-β1 with the MEK inhibitor U0126 and determined the expression of CDH1 and SNAI1. Interestingly, U0126 partially prevented the RAC1B knockdown-induced decrease in basal CDH1 expression and TGF-β1-induced downregulation of CDH1 ( Figure 5A ) as well as the RAC1B knockdown-induced increase in basal SNAI1 expression and TGF-β1-induced upregulation of SNAI1 ( Figure 5B ) at both the protein ( Figure 5A ,B) and RNA (Supplementary Figure S6) level.
The ability of U0126 to partially restore CDH1 and suppress SNAI1 expression in RAC1B-depleted Panc1 cells led us to hypothesize that inhibition of ERK activation should also be able to relieve the inhibitory effect of RAC1B on cell migration (see Figure 2C ). To this end, treatment of Colo357 cells with U0126 potently relieved the migratory activity in RAC1B knockdown cells ( Figure 5C ).
These results suggested the possibility that RAC1B mediates its stimulatory effect on epithelial genes and its inhibitory effect on mesenchymal genes as well as on cell migration by suppression of MEK-ERK signaling. To study this more directly, we treated Panc1-RAC1B-KO and control cells with TGF-β1 for various times and subjected them to immunoblot detection of phosphorylated forms of ERK1 and ERK2, as indicators of their activation ( Figure 5D ). Intriguingly, a time-course analysis indicated a biphasic activation pattern with a particularly strong increase in TGF-β1-dependent phosphorylation of ERK2 in RAC1B-KO cells at 15 min and 1 h after TGF-β1 addition. Moreover, ERK2 activation was prolonged, reaching levels of control cells only after the 4 h time point ( Figure 5D ). The results show that RAC1B promotion of basal CDH1 expression and prevention of TGF-β1-induced silencing of CDH1 as well as RAC1B inhibition of basal SNAI1 expression and prevention of TGF-β1-mediated activation of SNAI1 involves suppression of MEK-ERK signaling. As a functional consequence of these events, RAC1B acts as a potent inhibitor of EMT and cell migration. 
Discussion
In a previous study evaluating RAC1B protein expression immunohistochemically in tissue biopsies of human PDAC, we found that RAC1B expression correlated significantly with patient survival [18] . Since less malignant carcinomas usually have retained a higher degree of differentiation, this already suggested a possible link between RAC1B and the epithelial phenotype. Unfortunately, due to a limited number of samples for each of the three subgroups (G1, G2, G3) it was not possible to correlate RAC1B with differentiation grade. Here, we studied in more detail the 
In a previous study evaluating RAC1B protein expression immunohistochemically in tissue biopsies of human PDAC, we found that RAC1B expression correlated significantly with patient survival [18] . Since less malignant carcinomas usually have retained a higher degree of differentiation, this already suggested a possible link between RAC1B and the epithelial phenotype. Unfortunately, due to a limited number of samples for each of the three subgroups (G1, G2, G3) it was not possible to correlate RAC1B with differentiation grade. Here, we studied in more detail the role of RAC1B in maintaining a differentiated cellular phenotype. Using a panel of PDAC-derived cell lines with a high or low grade of differentiation, we observed that RAC1B was more abundant in well differentiated PDAC lines as opposed to poorly differentiated lines (see Figure 1) . A higher abundance of RAC1B expression in more differentiated lines was also observed among a panel of eight lung adenocarcinoma cell lines [33] . This suggested the attractive possibility that the correlation of RAC1B expression with the cells' differentiation grade is not only an epiphenomenon but is functionally involved in maintaining the epithelial phenotype, i.e., by promoting the expression of epithelial genes. To this end, we show that CDH1 as well as other genes that determine the epithelial phenotype were downregulated upon RAC1B knockdown and upregulated following forced RAC1B overexpression. Our results on RAC1B regulation of CDH1 contrast with those of another study in human colon cancer cells in which E-cadherin expression was found to be negatively regulated by RAC1B [34] . Whether these conflicting observations are due to tissue-specific differences is currently unclear.
In Panc1 cells, CDH1 was dramatically downregulated by TGF-β1 and RAC1B knockdown was able to enhance this effect while ectopic overexpression of RAC1B antagonized the TGF-β1-dependent repression of CDH1. Besides its role as a promoter of epithelial gene expression we identified RAC1B as a powerful inhibitor of basal and TGF-β1-induced mesenchymal gene expression. This applies for mesenchymal genes with different functions and from different classes such as intermediate filament proteins (Vimentin), receptors involved in TGF-β signaling (ALK5, PAR2), proteinases involved in TGF-β1 activation and matrix turnover (MMP9, PAI-1) as well as master regulators of EMT (SNAIL, SLUG). The coordinated induction of epithelial genes and the concurrent suppression of mesenchymal genes and spontaneous cell migration suggests that RAC1B is a central player and an endogenous RAC1 antagonist in the EMT program ( Figure 6 ). In view of the data presented in this study the proposed role of RAC1B as a driver of EMT and tumor progression in PDAC remains questionable and requires careful reassessment. Rac1b has been reported to promote cell migration and EMT induced by MMP3 [15, 16] , although this conclusion was based on data from only one epithelial cell line of murine breast origin. In work carried out on a panel of lung adenocarcinoma cell lines we found that ectopic RAC1B expression was associated with increased E-cadherin and decreased Vimentin expression and in contrast to RAC1 was unable to induce EMT and invasive activity in an in vivo chorioallantoic invasion model [33] . Moreover, in a transgenic mouse model of lung adenocarcinoma, Rac1b expression alone was insufficient to drive tumor initiation and was not required for K-ras driven cell proliferation [41] . Likewise, in another mouse model of inflammation-induced colon cancer, Rac1b overexpression failed to drive intestinal neoplasia in the absence of an oncogenic driver like Apc [42] . In a study on human PDAC, we found that RAC1B expression was primarily found in the tumor cells and was positively correlated with patient survival [18] . In contrast, a study by Mehner and colleagues found in human PDAC tissue biopsies a strong correlation of MMP3 and RAC1B expression levels in all tumor stages and a Figure 6 . Cartoon illustrating the role of RAC1B in negative regulation of the epithelial-mesenchymal transition (EMT) program in (pancreatic) epithelial cells. Upon exposure to EMT inducers such as TGF-β1, epithelial cells-characterized by high RAC1B and E-cadherin expression, and low SNAIL-activate MEK-ERK signaling leading to downregulation of epithelial marker genes such as CDH1 and concomitant upregulation of mesenchymal marker genes such as SNAI1. The resulting mesenchymal phenotype is characterized by low RAC1B and E-cadherin expression but high SNAIL expression, a spindle-shaped cellular morphology, and a motile phenotype. RAC1B blocks this transition by interfering with TGF-β1-induced activation of the ERK pathway and in particular ERK2. Green arrows indicate activation, while the red line indicates suppression. For details see text.
The molecular basis for the antagonistic effects of RAC1 and RAC1B on EMT and cell motility may be related to different signaling abilities. For instance, RAC1 but not RAC1B is able to interfere with cadherin-mediated adhesion and to destabilize cell-cell contacts, events that require activation of the RAC1 downstream target PAK1. However, RAC1B cannot activate PAK1, suggesting that this may contribute to the inability of RAC1B to disrupt cell-cell contacts and induce junction disassembly [35] . In PDAC cells we observed antagonistic effects of RAC1 and RAC1B on TGF-β1-dependent Smad signaling. Whereas RAC1 promotes Smad activation [36] , RAC1B inhibits it [18] and we were able to show that impaired Smad signaling by RAC1B is due to suppression of ALK5 and PAR2 [20, 21, 37] . In the present study we provide evidence that antagonism of RAC1B and RAC1 extends to regulation of E-cadherin expression, cell migration, and the MEK-ERK signaling pathway. While RAC1 can sustain EMT through activation of MEK1/2 [10] , we revealed here a strong inhibitory effect of RAC1B on ERK activation, particularly on ERK2. Experiments involving pharmacological blocking of MEK revealed that suppression of ERK is involved in RAC1B-mediated inhibition of cell migration, prevention of TGF-β1-induced downregulation of CDH1 and TGF-β1-mediated upregulation of SNAI1 (see Figure 5) . While MEK-ERK signaling has been implicated before in downregulation of CDH1 by epidermal growth factor, serine protease inhibitor Kazal type 1, and activin B [38] [39] [40] , our observation that TGF-β employs the same pathway to silence CDH1 is novel. The partial reversal of migratory activity in RAC1B knockdown cells and the TGF-β1-dependent decrease in E-cadherin expression by U0126 may be secondary to U0126-mediated inhibition of TGF-β1-induced upregulation of SNAIL since SNAIL is a potent inhibitor of CDH1. These results are in line with recent data showing that RAC1B suppression of PAR2 (a prerequisite for subsequent downregulation of ALK5) could be rescued by inhibition of MEK [21] .
In view of the data presented in this study the proposed role of RAC1B as a driver of EMT and tumor progression in PDAC remains questionable and requires careful reassessment. Rac1b has been reported to promote cell migration and EMT induced by MMP3 [15, 16] , although this conclusion was based on data from only one epithelial cell line of murine breast origin. In work carried out on a panel of lung adenocarcinoma cell lines we found that ectopic RAC1B expression was associated with increased E-cadherin and decreased Vimentin expression and in contrast to RAC1 was unable to induce EMT and invasive activity in an in vivo chorioallantoic invasion model [33] . Moreover, in a transgenic mouse model of lung adenocarcinoma, Rac1b expression alone was insufficient to drive tumor initiation and was not required for K-ras driven cell proliferation [41] . Likewise, in another mouse model of inflammation-induced colon cancer, Rac1b overexpression failed to drive intestinal neoplasia in the absence of an oncogenic driver like Apc [42] . In a study on human PDAC, we found that RAC1B expression was primarily found in the tumor cells and was positively correlated with patient survival [18] . In contrast, a study by Mehner and colleagues found in human PDAC tissue biopsies a strong correlation of MMP3 and RAC1B expression levels in all tumor stages and a significant association of the subcellular distribution of RAC1B with patient outcome [43] . However, the issue of whether RAC1B is causally involved in tumorigenesis or whether its overexpression is merely an epiphenomenon remains open as this study did not provide functional data from cell culture models on the consequences of selective RAC1B knockdown for tumor cell EMT or invasion. Moreover, given the overexpression/hyperactivation of the related RAC1 in PDAC, the ability of MMP3 to induce RAC1 activation [44] , and the association of increased activation of MMP3 and upregulation of RAC1 [45] , it may well be that RAC1 rather than RAC1B accounted for the putative protumorigenic effect. Based on the results of this study, we speculate that RAC1B overexpression rather than being a driver of tumor progression represents a cellular defense mechanism against TGF-β or inflammatory cytokine-induced EMT and eventual malignant conversion. In support of this hypothesis are data from a murine colon cancer model showing that Rac1b can alleviate carcinogen/acute inflammation-associated carcinogenesis [42] .
Tumor budding has been associated with EMT and occurs frequently in pancreatic cancer [7, 46] . It is defined as the presence of detached, isolated single cells or small cell clusters scattered in the stroma at the invasive tumor front, essentially reflecting a type of diffusely infiltrative growth. Raf-1 kinase inhibitor protein (RKIP) has been identified as a protein with lower expression in the tumor buds/front compared to the tumor center [47] . Moreover, loss of RKIP is associated with the presence of nodal and/or distant metastases as well as reduced patient survival and hence may be used as a predictor of high-grade tumor budding, tumor aggressiveness, and unfavorable outcome [48] . Remarkably, the loss of RKIP or RAC1B share several consequences in common: the appearance of morphological hallmarks of EMT and an increase in cell motility [17, 47] , a decrease in E-cadherin and an increase in Vimentin, SNAIL, and SLUG expression [47] , as well as derepression of MEK-ERK and p38 MAPK signaling [47, 49] . It therefore appears that selective loss of RKIP in the tumor buds can drive tumor progression and eventually metastatic disease. Given the anti-EMT and anti-migratory function of RAC1B, it is tempting to speculate that a similar scenario also holds true for RAC1B.
Conclusions
The data presented in this study revealed an unexpected dual functional role for RAC1B in pancreatic epithelial cells, (active) maintenance of a differentiated (epithelial) phenotype, and protection from (TGF-β1 driven) EMT and cell motility (Figure 6 ). High RAC1B, or a high ratio of RAC1B to RAC1 expression, may thus pose a barrier against malignant transformation and together with its potent antimigratory function in vitro, RAC1B qualifies as a genuine tumor suppressor protein. Therefore, strategies to increase its expression over that of its protumorigenic relative, RAC1, may be desirable from a therapeutic perspective. Table S1 : Primers used for qPCR.
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